Recent advances in targeted therapy for ovarian cancer  

作　　者：Tianyu Qin Gang Chen 

机构地区：[1]National Clinical Research Center for Gynecology and Obstetrics,Cancer Biology Research Center,Department of Gynecology and Obstetrics,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China

出　　处：《Oncology and Translational Medicine》2022年第1期28-35,共8页肿瘤学与转化医学（英文版）

摘　　要：The global burden of ovarian cancer is gradually increasing while patients still suffer from relatively limited treatment options.With recent advances in the decoding of the molecular landscape of ovarian cancer,more options in targeted strategy were offered and can therefore be tailored in different clinical settings for individual patient.Targeting of the abnormal angiogenesis process is the first significant clinical breakthrough which revolutionized the treatment of advanced ovarian cancer,followed by the advent of poly-(ADP)-ribose polymerase(PARP)inhibitors.These two strategies represented by bevacizumab and olaparib respectively underwent tests of numerous clinical trials.In recent years,immune checkpoint inhibitors(ICIs)have been incorporated into the blueprint of ovarian cancer treatment though the effectiveness still left much to be desired.Herein,we systematically outlined recent advances in targeted therapy for ovarian cancer and summarized the landmark clinical trials for each targeted therapy including angiogenesis inhibitors,PARP inhibitors and ICIs.

关 键 词：ovarian cancer targeted therapy ANTI-ANGIOGENESIS poly-(ADP)-ribose polymerase(PARP)inhibitor immune checkpoint inhibitor(ICI) clinical trial 

分 类 号：R737.31[医药卫生—肿瘤]